Anna welcome to countdown everybody. First, we are going to hear from Credit Suisse. Were going to hear from roche. Mark it is a big day from roche as they report earnings. Anna we will speak to caroline about how the business is reporting. Anna sales rose 6 at a constant foreignexchange rate. We are confirming the for your outlook. Mark absolutely. We are waiting on the net income. Missing estimates come at 7. 22. We were looking at 7. 38. That is core eps. It is a really interesting day for roche. In terms of the sales forecast. This is a company that, over the last year, has really trailed the pharmaceutical sector. Anna comparatively, to the rest of the pharmaceutical sector. Mark 7 versus 32 . Anna 9. 2 4 billion, and ahead of the estimate. It seems to be a mixed bag when comparing sales and those estimates. The foreignexchange eroded. That is a very important conversation to have. Also it is interesting to talk about how they will keep a lid on their costs in the second half. The